Martin D Madaus has bought stock on 6 days since Aug 2022

Dr. Martin D. Madaus is a globally experienced healthcare and life sciences executive who serves as Chair of the Board and director at Repligen Corporation (NASDAQ: RGEN), having joined the company’s Board in February 2023 and been elected Chair effective March 13, 2026.( He brings more than 25–36 years of industry experience, including five years as Chairman, President and Chief Executive Officer of Millipore Corporation, where he played a central role in transforming the company into a leading life science tools provider and in its acquisition by Merck KGaA in 2010.( In addition to his responsibilities at Repligen, Dr. Madaus is an active board leader, serving on the boards of public companies such as Azenta, Inc. and Hologic, Inc., and has previously held roles including Lead Director at Quanterix Corporation and Board member at Standard BioTools, Inc. (formerly Fluidigm).(

Over his career, Madaus has held multiple chief executive positions across the diagnostics and life science tools sectors, including Chairman and CEO of Ortho Clinical Diagnostics and President and CEO, North America, at Roche Diagnostics Corp., following earlier sales and marketing roles at Boehringer Mannheim Corporation.( He also serves as a senior operating executive at The Carlyle Group and chairs the boards of private companies such as Unchained Labs, Emulate, Inc., and UltiVue Inc., reflecting his focus on strategy, governance, and operational excellence in growth-oriented healthcare businesses.( Dr. Madaus began his professional life as a veterinarian and holds a D.V.M. from the University of Munich and a Ph.D. in veterinary medicine from the University of Veterinary Medicine Hannover in Germany, underpinning his longstanding engagement with health and life sciences innovation.(

Written by Perplexity from public sources.